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ABSTRACT
The aim of this study was to report the clinical results of reduced pelvic ﬁeld radiotherapy (RT), excluding the
anastomotic site, after total mesorectal excision in selected patients with rectal cancer. Between 2011 and 2014,
99 patients underwent upfront surgery for clinically less-advanced tumors but were ﬁnally diagnosed as pT3/N+.
Among them, 50 patients with mid–upper rectal cancer who received postoperative RT with a reduced pelvic ﬁeld
were included in this retrospective review. This group was composed of patients with high seated tumors, com-
plete resection with a clear circumferential resection margin, and no complication during surgery. We investigated
treatment outcomes, toxicity and the effect of RT-ﬁeld reduction on organs-at risk in 5 randomly selected
patients. During the median follow-up period of 42 months (range: 15−59 months), tumors recurred in 9 patients
(18%). The 3-year overall and disease-free survival were 98% and 81%, respectively. Distant metastasis was the
dominant failure pattern (n = 8, 16%), while no recurrences occurred at or near anastomotic sites. No anasto-
motic complications were found on pelvic examination, images and/or colonoscopy. Reported acute and late RT-
related toxicities were mostly mild to moderate, with only small numbers of Grade 3 toxicities. None of the
patients developed Grade 4−5 acute or late toxicity. With a caudally reduced ﬁeld, 64% reduction in absolute
anastomotic exposure at the maximum dose was achieved compared with the traditional whole-pelvic ﬁeld
(P = 0.008). The reduced pelvic ﬁeld RT was able to minimize late anastomotic complication without increasing
its recurrence in selected patients with mid–upper rectal cancer in the postoperative setting.
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INTRODUCTION
In recent years, improvements in diagnosis, staging, and multimodal
treatments have provided both local control and survival beneﬁts to
patients with rectal cancer [1, 2]. There is considerable evidence
that for many patients with locally advanced rectal cancer, pelvic
radiotherapy (RT), in addition to total mesorectal excision (TME),
results in improved local control and increased probability of
sphincter preservation in low-seated tumors [3, 4]. Although pre-
operative RT is the standard of treatment for locally advanced
tumors [5, 6], a substantial number of patients still require post-
operative chemoradiotherapy (CRT) for unfavorable pathologic fea-
tures after upfront surgery for less-advanced tumors. Nevertheless,
there is also substantial evidence that the use of pelvic RT may be
associated with early and late adverse effects, such as wound
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complications, impaired anal function and fecal incontinence,
increased risk of late bowel obstruction, and even more serious con-
sequences, such as secondary malignancies [7–9]. It therefore
appears that balancing the potential survival beneﬁt and the toxicity
risk is important when planning RT, in order to adapt the dose dis-
tribution to targets so as to avoid normal tissue, thereby maximizing
the therapeutic ratio.
Multiple factors, including surgical modality, circumferential
resection margin (CRM) status, risk classiﬁcation group based on
Gunderson’s pooled analysis [10], distance from the anal verge,
total nodal count (as a surrogate of surgical quality), and perforation
in the tumor area, has an impact on the risk of local recurrence
(LR) and patterns of failures. A comparison of failure patterns has
suggested that the presacral space is the dominant site of local
recurrence after surgery + RT or CRT in the TME era [3]. The
anastomosis, which is one of the common involvement sites, is asso-
ciated with residual mesorectal fat after incomplete surgery. High-
seated tumors are associated with low rates of LR, since it is
possible to achieve a clear resection margin at the rectum above the
peritoneal reﬂection, and surgery in this region is technically less
demanding [3, 11, 12]. In addition, lymphatic spread occurs mainly
in the upward direction, along the inferior mesenteric nodes, in
high-seated tumors [13]. Taken together, at our institution, a multi-
disciplinary consensus was reached in 2011 to implement a caudally
reduced radiation ﬁeld excluding the anastomotic site, for selected
patients in the post-operative clinical setting. To implement this
approach, the tumors should be high-seated, with a relatively low
risk of LR (complete TME, adequate CRM, and without perforation
of or leakage from the anastomotic site during surgery).
In this study, we investigated the clinical outcomes of RT using
a reduced ﬁeld in locally advanced rectal cancer with a mid–upper
location, by reviewing the patterns of failure, efﬁcacy, and toxicity,
and attempted to determine whether this reduced ﬁeld RT could be
performed safely in carefully selected patients. In addition, the
potential beneﬁt in terms of the irradiated dose at the anastomotic
site was determined by dosimetric comparison for use of the con-
ventional three-ﬁeld whole-pelvic ﬁeld with use of the reduced pel-
vic ﬁeld.
MATERIALS AND METHODS
Patients
The schematic ﬂow of patient selection is shown in Fig. 1. In brief,
postoperative CRT was recommended for all TME patients who
received no preoperative treatment with a CRM involvement, had
perforation in the tumor area, and/or with a diagnosis of ≥pT3 or
pN+ rectal cancer. A total of 99 patients with pT3 or pN+ (no T4)
rectal cancer received TME from March 2011 to September 2014 at
our institution. (i) Traditional pelvic ﬁeld radiation was used in
cases of R1/2 resection (n = 15), low-seated tumors (n = 13), sur-
gical complications (n = 13), and technical issues that limited the
use of a reduced pelvic ﬁeld (n = 7). (ii) The remaining 51 patients
who underwent complete TME, with a clear CRM, for high-seated
tumors, and who were without surgical complications and technical
limitations, received reduced-ﬁeld RT. After excluding 1 patient
who could not receive the full course of RT, 50 patients were
included in this analysis. In addition, 491 patients received pre-
operative CRT during the same period. The level of the tumor was
classiﬁed according to the peritoneal reﬂection, using T2-weighted
sagittal images obtained by magnetic resonance imaging (MRI),
as being high- (upper) or low-seated (lower-middle) tumors, as
described in a previous report [14]. Low- or mid-rectal cancers
were divided using a virtual line, which was deﬁned as the line from
the symphysis pubis to the levator muscle origin on the sacrum on
the sagittal T2-weighted images. The details of data collection are
described in Supplementary Text 1. This study was approved by the
institutional review board (IRB) of the Yonsei University Health
System. The patient records/information was anonymized and de-
identiﬁed prior to this retrospective analysis, so informed consent
was not obtained from each participant.
Radiotherapy
Postoperative RT was delivered in a reduced pelvic ﬁeld with a radi-
ation dose of 45 Gy, divided into 25 fractions, in a single phase,
using 3D conformal RT. Contrast-enhanced computed tomography
(CT), with slices of 5-mm-thickness, was performed to plan the
RT; the patient was instructed to maintain a full bladder in the
prone position using a belly board with bladder compression device
during the planning CT scan. Protocol-based full-bladder mainten-
ance (which consisted of education, training and continuous bio-
feedback by measuring bladder volume) was performed throughout
the treatment sessions [15, 16]. The CT scan was imported to the
Pinnacle planning system version 9.4 (Philips Medical Systems,
Cleveland, OH) and MIM software version 6.0.6 (MIM Software
Inc., Cleveland, OH), and the clinical target volume (CTV) was
delineated on each of the axial CT images by an experienced radi-
ation oncologist.
Fig. 1. Flow chart of patients with rectal cancer who were
treated with upfront TME ± postoperative RT in our
institution (January 2011 − September 2014). Asterisk
indicates postoperative RT in reduced pelvic ﬁeld (n = 51);
of the 51 patients, 50 patients were included in our analysis.
Dagger indicates the height of the tumor is classiﬁed as
upper, mid, or low, according to the location of the tumor
on T2-weighted sagittal MRI scans, as described in a
previous report [14].
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The CTV was not a classic pelvic volume, but was a caudally
reduced pelvic ﬁeld that omitted the anastomotic site. The CTV
comprised the presacral, perirectal, internal iliac, and obturator
lymph node areas. Its outline was made 1−1.5 cm above the level of
the anastomotic site, with an intention to avoid irradiation of this
site. The CTV included parts of the bladder anteriorly and parts of
the sacrum posteriorly, considering possible motion in that area dur-
ing the treatment. A 3–5 mm set-up uncertainty margin was applied
to the CTV to create the planning target volume (PTV). The upper
limit of the reduced pelvic irradiation ﬁeld was S1, and the lower
limit was 1 cm below the PTV. A 6-MV posterior photon beam and
10-MV lateral opposing photon beams were used for the reduced
pelvic ﬁeld (Fig. 2). All ﬁelds were treated daily. Port ﬁlms were
obtained weekly, or more often if clinically indicated.
Plan comparison
We performed a dosimetric comparison between the reduced-ﬁeld
and traditional three-ﬁeld whole-pelvic ﬁeld in ﬁve randomly
selected patients. An additional RT plan was generated in the trad-
itional whole-pelvic ﬁeld (45 Gy, in 25 fractions) for each patient,
and Dmax, Dmean, V30 and V40 of each organ at risk (OAR) were
compared. OARs included the small bowel, bladder, anus, and bilat-
eral femur heads. We contoured the ‘anastomosis’ OAR, including
the rectum and perirectal tissue, on each slice demonstrating the
anastomosis, to compare the irradiated dose at the anastomosis.
Toxicity and treatment outcome
Patients were seen by a clinician at least weekly during RT and at 1
month after completion of RT, to assess toxicity and to perform a
complete blood count (CBC) test. Toxicity was scored according to
the Common Terminology Criteria for Adverse Events (CTCAE
v. 4.0). Acute toxicity was deﬁned as any event occurring during RT or
within 3 months of treatment completion, and late toxicity was deﬁned
as events occurring later than 3 months after the end of treatment.
Patients were evaluated at 3-month intervals for the ﬁrst year,
6-month intervals for the next 2 years, and 12-month intervals
Fig. 2. Example of reduced pelvic ﬁeld. (a) An example of PTV delineation on each slice of the planning CT scan. The beam’s
eye views of the right lateral ﬁeld (b) and postero–anterior ﬁeld (c). (d) An isodose curve of the reduced pelvic ﬁeld. The
anastomotic site (white arrowhead) is not included in the irradiation ﬁeld.
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thereafter. Routine follow-ups included colonoscopy, serum carci-
noembryonic antigen (CEA) tests, abdominal CT and/or pelvic
MRI, and toxicity evaluation. When recurrence was suspected, fur-
ther assessments were performed by colonoscopy with histological
conﬁrmation and imaging studies, including MRI. LR was deﬁned as
any recurrence inside the pelvis, with or without extrapelvic recur-
rences. All other recurrences were deﬁned as distant metastases
(DMs).
Statistical analysis
SPSS ver. 20 (IBM, Armonk, NY, USA) was used for statistical ana-
lyses. Recurrence-free survival (RFS), local recurrence–free survival
(LRFS), distant metastasis–free survival (DMFS) and overall sur-
vival (OS) rates were deﬁned as the time from the date of surgery
to any recurrence or last follow-up, to local recurrence or last
follow-up, to distant metastasis or last follow-up, and to death from
any cause or last follow-up, respectively. These rates were calculated
using the Kaplan−Meier method, and prognostic impacts of clinical
factors were analyzed with the log-rank test. Cox regression was
used for identiﬁcation of independent prognostic factors by multi-
variate analysis. P-values <0.05 were considered statistically
signiﬁcant.
RESULTS
Clinical and pathological characteristics
In this group of patients, 42% of tumors were located in the upper-
third and 58% were located in the mid-third of the rectum. In terms
of the initial clinical American Joint Committee on Cancer (AJCC)
stage, all except for 1 patient, who could not receive preoperative
CRT due to urgent cardiac problems, were diagnosed as having
cT1/2 (n = 11, 22%) or early cT3 stage (n = 37, 74%) tumors.
Sixteen patients (32%) were diagnosed with clinical N+ stage.
Forty-nine patients (98%) underwent low anterior resection (LAR),
and all patients received complete resection (R0).
In the ﬁnal pathological AJCC stage, all patients had pT3
(n = 32, 64%) or pN+ (n = 39, 78%) stage tumors, and 29 patients
(58%) were classiﬁed as belonging to the intermediate-risk group
(pT1N1, pT2N1, pT3N0). Patient and tumor characteristics are
summarized in Table 1. Details of chemotherapy regimens are
shown in Supplementary Text 2.
Table 1. Patients’ characteristics
Variables No. %
Age (year) Median 62 (34–81)
Sex
Male 35 70
Female 15 30
Tumor location
Upper 21 42
Mid 29 58
Clinical AJCC stage
cT1N0 1 2
cT1/2N0 6 12
cT1/2N1 1 2
cT2N0 3 6
cT2/early cT3N0 2 4
cT2/early cT3N1 3 6
Early cT3N0 21 42
Early cT3N1 11 22
Advanced cT3N2 1 2
Unknown 1 2
Pathologic AJCC stage
pT1N1 3 6
pT2N1 15 30
pT3N0 11 22
pT3N1 16 32
pT3N2 5 10
PNE
Positive 6 12
Negative 44 88
LVI
Positive 12 24
Negative 38 76
PNI
Positive 6 12
Negative 44 88
Continued
Table 1. Continued
Variables No. %
Proximal margin (cm) Median 8.9 (1.0–17.0)
Distal margin (cm) Median 2.3 (1.0–27.0)
Circumferential margin (cm) Median 1.0 (0.3–2.2)
AJCC = American Joint Committee on Cancer; PNE = perinodal extension;
LVI = lymphovascular invasion; PNI = perineural invasion. Clinical T3 stage rec-
tal cancers are classiﬁed as more advanced stage T3 tumors (‘Advanced
cT3’, >5 mm invasion outside the muscularis propria) or early stage T3 tumors
(‘Early cT3’, ≤5 mm invasion outside the muscularis propria) using preoperative
MRIs.
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Patterns of recurrence
During the median follow-up period of 42 months (range: 15−59
months), tumors recurred in 9 patients (18%). DM was the domin-
ant failure pattern (n = 8, 16%), while LR occurred in only 1
patient (2%), at 9 months postoperatively (Supplementary
Table 1). The majority of recurrences were discovered in patients
with pT3 stage tumors (DM 7, LR 1). In the latter patient with LR,
the recurring tumor was located in the presacral area, which was
included in the irradiated area and was associated with multiple
adverse pathological features (poorly differentiated adenocarcinoma,
with signet ring cell features, multiple regional LNs (10/27), lym-
phovascular invasion (LVI) and perineural invasion (PNI). In the 8
patients with DM, the metastases occurred mostly within 1 year
(median: 9.5 months) after surgery. DMs were most commonly
observed in the lung (n = 4), while others were observed in the
liver (n = 1), liver and lung (n = 1), liver and portocaval/hepato-
duodenal lymph nodes (n = 1), or peritoneum (n = 1).
Toxicity
There were no anastomotic complications after surgery, based on
pelvic examination, imaging, and/or colonoscopy, up to the last
follow-up date. Reported acute and late RT-related toxicities were
mostly mild to moderate, with only small numbers of Grade 3 toxi-
cities. Acute toxicities included fatigue, anorexia, nausea, cystitis,
diarrhea, anal incontinence, or skin rash, and late toxicities included
diarrhea or anal incontinence (Table 2). The only Grade 3 toxicity
observed was diarrhea [acute: 15 (30%), late: 13 (28%)]. None of
the patients developed Grade 4−5 acute or late toxicity.
Survival and prognostic factors
The RFS, LRFS, DMFS and OS rates at 3-year follow-up were 81%,
98%, 83% and 98%, respectively (Fig. 3). Only the survival rates for
patients with T3 stage tumors were slightly worse (75%, 96%, 78%
and 95%, respectively). At the last follow-up, only 1 disease-related
death had occurred, at 27 months after surgery, after DM involving
both the liver and the lung. Clinical features were then evaluated to
determine their prognostic signiﬁcance for RFS, and the following
factors were found to be related to worse RFS in univariate analysis:
N2 stage, Stage IIIC, LVI and PNI (all Ps < 0.05). Among these
factors, LVI was the only signiﬁcant factor in multivariate analysis
(P = 0.039) (Supplementary Table 2).
Dosimetric comparison
Compared with the traditional whole-pelvic ﬁeld RT, a signiﬁcantly
lower dose was delivered to the anus and anastomosis by using the
reduced pelvic ﬁeld. Although the dose varied according to the
height of the pelvis and the anastomosis, Dmax was reduced by an
average of 6% and 36% at the anus and anastomotic site, respect-
ively. The average values of Dmax, Dmean, V30 and V40 of other
OARs were all similar (Table 3).
Table 2. Incidence of acute and late toxicity after radiotherapy
Grade Acute toxicity [No. (%)] Late toxicity [No. (%)]a
Fatigue Anorexia Nausea Cystitis Diarrhea Anal incontinence Skin rash Diarrhea Anal incontinence
0 8 (16) 11 (22) 45 (90) 43 (86) 20 (40) 41 (82) 48 (96) 10 (21) 43 (92)
1 35 (70) 33 (66) 4 (8) 6 (12) 4 (8) 8 (16) 0 (0) 8 (17) 4 (8)
2 7 (14) 6 (12) 1 (2) 1 (2) 11 (22) 1 (2) 2 (4) 16 (34) 0 (0)
3 0 (0) 0 (0) 0 (0) 0 (0) 15 (30) 0 (0) 0 (0) 13 (28) 0 (0)
aThree patients with unknown late toxicity information were excluded.
Fig. 3. Survival curves: (a) overall survival (OS) and recurrence-free survival (RFS), and (b) local recurrence–free survival
(LRFS) and distant metastasis–free survival (DMFS) rates in 50 patients.
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DISCUSSION
This study investigated the possibility that using a reduced pelvic ﬁeld
RT, which spared the anastomotic site, could minimize late anasto-
motic complications, without increasing tumor recurrence in selected
rectal cancer patients in the postoperative setting. The selection pro-
cess included a consideration of (i) the completeness of TME with a
clear CRM, (ii) the location of the tumor (mid/upper tumors were
selected) and (iii) the complete absence of postoperative complica-
tions. We observed a non-increased risk of recurrence or late compli-
cations at the anastomotic site, up to the median follow-up period of
42 months. Thus, our study suggests that reduced-ﬁeld RT can be
used postoperatively with success in carefully selected patients.
Since the introduction of TME, local failure has decreased dra-
matically, with further improvement in treatment success brought
about by addition of pelvic RT. In a Dutch trial with a median
follow-up of 12 years, the 10-year LR rates were 5% in the
RT + TME group and 11% in the TME-only group [4]. It has also
been reported that there are many pathological or therapeutic fac-
tors that affect the risk of LR in the TME era. First, one of the
major prognostic factors of LR after resection is a positive CRM
and/or distal resection margin, with the probability of residual
tumors. CRM involvement was found to be a risk factor for LR as
well as DM in several studies, including the Dutch TME trial, which
reported a 17% LR rate in patients in whom the CRM was involved
[3, 17, 18]. A study from the Memorial Sloan−Kettering Cancer
Center found that residual tumors were observed more frequently
when the tumor was distally located [19]. It has generally been
recommended that a distal margin of 1−2 cm be used in TME to
assure removal of all local diseased tissue. Even a distal margin of 1
cm was considered sufﬁcient to eliminate all occult tumor exten-
sions beneath the gross mucosal edge in patients receiving pelvic
RT plus TME [19]. Second, the location of the tumor within the
rectum is also a critical factor, as high-seated tumors are covered by
the peritoneum and a clear margin is more easily achievable with
TME. The LR rate was reported as 10−15% for tumors located in
the lower third, which was higher than for tumors located in either
the middle third (5−10%) or upper third (2−5%) [11, 12].
Therefore, it is plausible that mid–upper rectal cancers with a sufﬁ-
cient clear surgical margin would have a relatively low risk for LR.
Some knowledge of the anatomic pattern of LRs after rectal can-
cer surgery would aid in deﬁning the optimal RT target volume.
Earlier studies [20] assessed the predominant location of LRs, and
deﬁned the guidelines for delineation of a CTV that includes the
primary tumor, the mesorectal subsite, the posterior pelvic subsite,
and the lateral lymph nodes. Although limited data are available on
failure patterns in the TME era, LR remains the predominant pat-
tern of failure, and presacral recurrences were the most common
type of LR (25% with TME alone, and 15% with TME + RT,
according to the Dutch TME trial) [3]. Presacral recurrences had a
generally poor prognosis, with an OS rate of 22.5%. Anastomotic
recurrences were less common (9% with TME alone, 5% with
TME + RT) and had a relatively good prognosis. Anastomotic
recurrence has traditionally been attributed to inadequate resection
margins or implantation of exfoliated cancer cells when creating the
anastomosis. Syk et al. reported that high-seated tumors showed
Table 3. Irradiated dose and volume for OARs in
conventional whole-pelvis and reduced pelvic ﬁeld
OAR Whole pelvis Reduced pelvis P valuea
Small bowel
Dmax (Gy) 29.82 29.96 0.917
V30 (%) 11.94 11.48 0.841
V40 (%) 9.92 9.46 0.841
Dmean (Gy) 9.83 9.57 0.690
Bladder
Dmax (Gy) 46.23 45.44 0.056
V30 (%) 51.54 41.23 0.421
V40 (%) 45.18 33.93 0.222
Dmean (Gy) 29.04 25.11 0.310
Anus
Dmax (Gy) 46.36 2.60 0.008
V30 (%) 79.05 0.00 0.008
V40 (%) 74.43 0.00 0.008
Dmean (Gy) 37.19 1.67 0.008
Anastomosisb
Dmax (Gy) 46.95 16.88 0.008
V30 (%) 100.00 2.76 0.008
V40 (%) 100.00 0.43 0.008
Dmean (Gy) 45.56 6.12 0.008
Rt. femur head
Dmax (Gy) 43.19 37.45 0.222
V30 (%) 58.89 16.26 0.056
V40 (%) 2.62 0.96 0.421
Dmean (Gy) 25.51 12.79 0.056
Lt. femur head
Dmax (Gy) 43.49 35.76 0.421
V30 (%) 50.76 15.89 0.032
V40 (%) 2.70 1.11 0.310
Dmean (Gy) 23.71 11.93 0.056
OAR = organ-at-risk.
aAnastomosis OAR was contoured, including rectum and perirectal tissue in each
slice showing anastomosis.
bThe Mann–Whitney U-test was used.
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LRs mainly in the anastomotic site, and most of these (12/14) were
accompanied by evidence of residual mesorectal fat [21]. In other
words, LR seldom recurred at the anastomotic site when no residual
tumors were left after surgery.
Anastomotic leakage (AL), one of the most detrimental compli-
cations after TME, could be associated with long-term oncological
outcomes, and with LR in particular. A recent systemic review [22]
has reported that the LR rate increased after AL in patients under-
going resection for colorectal cancer (odd ratios: 2.05, 95% CI: 1.51
−2.8, P = 0.0001). Although the mechanism by which AL may
enhance tumor recurrence remains uncertain, several studies sug-
gested that AL could lead to extra-luminal implantation of exfoliated
cancer cells from the bowel lumen or to local inﬂammatory
responses. Taken together, it can be inferred that TME with a clear
CRM, and high-seated tumors resected without surgical complica-
tions result in a low risk of recurrence at the anastomotic site, and
that LR will most frequently occur in the presacral area. Our ﬁnd-
ings of a low LR rate (2%, no outﬁeld LR) and high DM rate as a
predominant pattern of failure (16%) support this hypothesis.
Although RT delivers tumoricidal doses of radiation to the
microscopic tumor cells in the pelvic cavity, the normal tissue in the
irradiated ﬁeld is also subject to injury. In a postoperative RT trial,
13 patients (6.7%) overall had severe delayed reactions, including
small bowel obstruction, hemorrhage, enterocutaneous ﬁstula, and
rectal perforation [23]. Fractionated doses of RT induce a 15%
increase in the incidence of severe late complications in the small
bowel [24]. Hassan et al. demonstrated that patients receiving pelvic
RT had a higher rate of anastomotic complications, other than stric-
tures, including fecal incontinence, ﬁstulas, abscesses, and bowel
obstructions, than patients not receiving pelvic RT (5-year: 20% vs
5%, P = 0001) [25]. Although there have been some efforts to
reduce radiation doses to the small bowel in pelvic RT for rectal
cancers in recent years [21, 26–28], the effect of omitting the anas-
tomotic site in postoperative RT has not been investigated previ-
ously. It is plausible that a reduced dose and volume of radiation to
the anastomotic site will lead to reduced late toxicity without com-
promising local tumor control.
The effect on anal and anastomotic site exposure achieved by
using a reduced pelvic ﬁeld is shown in Table 3; an average 94%
and 64% reduction in Dmax was shown, respectively, as compared
with the typical three-ﬁeld whole-pelvic treatment approach. This is
likely to yield a signiﬁcant reduction in both acute and late bowel
and anastomotic toxicity. It should also be noted that, even up to
the last follow-up evaluation in our study, no acute or late toxicity
related to the anus or anastomotic site were observed. However, fur-
ther prospective studies with a longer follow-up duration are needed
to conﬁrm this observation, particularly in terms of late toxicity.
This study had some limitations. First, our study included a
small number of patients due to the low referral rates for post-
operative RT. Second, there is a possible patient selection bias due
to the retrospective study design. Because the majority of tumors
with high-risk features ﬁrst receive preoperative RT, tumors with a
relatively low risk of LR would be referred for postoperative RT.
However, even in patients with pN+ stage, perinodal extension,
LVI, or PNI, no LR occurred outside the smaller irradiated volume
used for RT in our study. A third limitation was the relatively short
follow-up duration, of a median of 42 months. However, this period
is quite adequate for considering the early outcome of postoperative
RT; it compares well with previous studies in the TME era that
reported a median of 17−30 months to LR [9, 27, 29]. Moreover,
the postoperative CRT group tended to develop early LR (<5
years) more often than the group receiving preoperative CRT, des-
pite the chance of late recurrences [30].
CONCLUSION
In conclusion, the use of a reduced pelvic ﬁeld, omitting the anasto-
motic site, for RT is a feasible postoperative treatment option for
clearly resected rectal cancers with a mid–upper location; this could
increase the safety of postoperative RT. Further studies with a long-
er follow-up duration, larger patient cohort, or a prospective setting
are warranted to conﬁrm these results.
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